1. Clinical Overview

Molecule: Synthetic fragment of Thymosin Beta-4 (Tβ4), containing the Lys-Asn-Pro-Asp (LKPD) core responsible for actin-modulating and wound-healing effects

Classification: Regenerative peptide fragment • Actin-binding protein modulator • Angiogenesis enhancer • Tissue-repair accelerator

Naturally occurring thymic peptide involved in tissue regeneration, actin cytoskeleton regulation, wound healing, angiogenesis, hair follicle stimulation, and anti-inflammatory effects. TB-500 is a highly bioavailable synthetic fragment designed to amplify Tβ4 reparative actions.

2. Mechanisms of Action

2.1 Actin Sequestration & Cellular Migration

Binds G-actin: cell migration, keratinocyte movement, fibroblast recruitment, myocyte repair, accelerated tissue remodeling. Enhanced muscle, tendon, ligament, dermal repair.

2.2 Angiogenesis

Upregulates VEGF, endothelial cell migration, microvessel formation, tissue perfusion. Improved oxygenation and nutrient delivery.

2.3 Anti-Inflammatory & Anti-Fibrotic

Reduces TNF-α, IL-6, neutrophil infiltration, fibrotic scarring. Better-quality scar and tendon healing.

2.4 Tissue Remodeling & Collagen

Myosin-actin cross-bridging repair, collagen organization, reduced adhesions, improved tensile strength.

2.5 Synergy with BPC-157

Feature	TB-500	BPC-157
Actin remodeling	Strong	Moderate
Angiogenesis	Strong	Strong
GI healing	Weak	Strong
Tendon/ligament	Strong	Strong
Nerve regeneration	Moderate	Strong
Inflammation control	Strong	Strong

3. Clinical Applications

3.1 Orthopedic & Sports Medicine

Muscle tears, tendonitis/tendinopathy, ligament sprains, overuse injuries, surgical recovery, fascia/myofascial repair. Reduced recovery time, improved tissue quality.

3.2 Wound Healing & Dermatologic

Faster wound closure, reduced inflammation, enhanced angiogenesis, smaller scars, improved re-epithelialization. Post-procedure: microneedling, laser resurfacing, RF needling, PRP rejuvenation, scar revision.

3.3 Cardiac & Vascular (Preclinical)

Reduced ischemia injury, improved cardiac cell survival, increased vascular density. Not standard of care.

3.4 Neurological (Emerging)

Reduced neuroinflammation, actin-mediated neuroregeneration, improved functional recovery. Limited clinical implementation.

4. Administration & Protocols

Loading (Weeks 1–6): 4–10 mg/week, divided 2–3 injections (common: 2 mg SC, 2–3×/week)
Maintenance (Weeks 7–12): 4–6 mg/month biweekly, or 2 mg weekly (athletic)
Localized Injury: 2–4 mg SC near injury, 1–3×/week ± peri-tendinous BPC-157

Injection Technique

SC: 29–31g needle, abdomen or near injury, well tolerated. IM: 25–27g needle, deeper muscle injuries, 2 mg/session.

Reconstitution

5 mg or 10 mg lyophilized vials. Standard: 2 mL bacteriostatic saline → 2.5–5 mg/mL. Alternative: 4 mL BS → 1.25–2.5 mg/mL. Refrigerate 7–14 days.

Oral TB-500

No reliable oral form with injection-comparable efficacy. Oral acts as adjunct only.

5. Clinical Decision Trees

Tree 1 — Should TB-500 Be Used?

Soft-tissue injury (muscle/tendon/ligament/fascia)? → YES — TB-500 recommended

Acute (<4 wk)? → TB-500 + BPC-157 immediately

Chronic (>4 wk)? → Longer loading phase

Rapid angiogenesis & inflammation reduction? → Strongly indicated

Contraindications? → Modify or avoid

Tree 2 — TB-500 vs BPC-157 vs Combination

Structural injury (muscle/tendon/ligament) → TB-500 primary + BPC-157 adjunct

Inflammatory or GI injury → BPC-157 primary

Accelerated orthopedic recovery → TB-500 + BPC-157 combined

Aesthetic post-procedure healing → TB-500 + GHK-Cu topical

6. Integrated Archetypes

A — Orthopedic Repair

Systemic: TB-500 4–6 mg/wk × 6 wk + BPC-157 500–750 mcg daily + oral RECOVER™
Local: Peri-tendinous BPC-157 + physical therapy

B — Athletic Performance & Recovery

TB-500 4 mg/wk × 4 wk + NAD+ or REVIVE™ mitochondrial + Glutathione IV

C — Post-Aesthetic Procedure

Systemic: TB-500 2–3 mg SC/wk × 2–4 wk + RECOVER™ (GHK-Cu + BPC-157) daily
Topical: GHK-Cu serum + PRiVIVE™ optional

D — High-Output Healing (Severe)

TB-500 8–10 mg/wk × 6 wk + BPC-157 1 mg/day (SC or oral RECOVER™)
Adjunctive: Shockwave + PRP + Glutathione IV

7. Contraindications

Absolute

Active cancer (angiogenic activity)
Pregnancy / Lactation
Known hypersensitivity

Relative

Uncontrolled autoimmune disease
Severe cardiac disease (angiogenesis caution)

8. Expected Timeline

Week 1–2: Reduced inflammation, improved mobility
Week 3–4: Accelerated healing, pain reduction
Week 4–6: Structural repair, improved performance
Post 6 weeks: Maintenance optional

9. Adverse Effects

Generally well tolerated. Temporary fatigue, injection-site irritation, mild headache, edema if over-dosed.

10. Monitoring

Pain scales
Range of motion
Physical performance
Ultrasound (tendon/ligament)
Post-procedure healing timelines
Inflammation markers (optional)

Legal Disclaimer

This document is provided solely for educational and informational purposes. TB-500 (Thymosin Beta-4 Fragment), BPC-157, and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — TB-500

Foundational Tβ4 Biology

1. Low, T. L. K., & Goldstein, A. L. Discovery of Thymosin Beta-4. PNAS, 72(1), 200–204 (1975).

2. Huff, T., et al. Tβ4 structure, function, cellular roles. Ann NY Acad Sci, 1112, 402–414 (2007).

3. Safer, D., et al. Tβ4 actin interaction/cytoskeletal regulation. PNAS, 88(14), 6608–6612 (1991).

TB-500 / Tβ4 Fragment Research

4. Sosne, G., et al. Active wound-healing fragments of Tβ4. J Biol Chem, 279(7), 5389–5396 (2004).

5. Smart, N., et al. Tβ4 fragments stimulate migration/repair. Nature, 474(7351), 444–448 (2011).

6. Shrivastava, S., et al. Tβ4 active domains repair/anti-inflammatory. FEBS Lett, 580(5), 1355–1360 (2006).

Wound Healing & Skin

7. Malinda, K. M., et al. Tβ4 accelerates wound healing. J Invest Dermatol, 113(1), 112–120 (1999).

8. Sosne, G., et al. Anti-inflammatory/reparative in dermal injury. Invest Ophthalmol Vis Sci, 43(3), 756–762 (2002).

9. Badamchi-Zadeh, A., et al. Fibroblast activation/collagen deposition. Matrix Biol, 65, 113–127 (2018).

Angiogenesis & VEGF

10. Philp, D., et al. Angiogenesis via Akt/endothelial migration. J Invest Dermatol, 121(6), 1441–1448 (2003).

11. Grant, D. S., et al. Endothelial migration/blood vessel formation. FASEB J, 9(14), 1379–1389 (1995).

12. Ho, J. H., et al. Endothelial repair after vascular injury. Atherosclerosis, 260, 59–67 (2017).

Orthopedic & Tendon

13. Kumar, A., et al. Tendon healing/collagen alignment. J Orthop Res, 29(12), 1973–1979 (2011).

14. Morris, D., et al. Rotator cuff tendinopathy. Am J Sports Med, 39(5), 1029–1036 (2011).

15. Chen, C. H., et al. Ligament regeneration. J Cell Mol Med, 17(12), 1608–1620 (2013).

16. Domingo-Sananes, M. R., et al. Chondroprotection in cartilage degeneration. Osteoarthritis Cartilage, 21(8), 1130–1138 (2013).

Myocardial & Ischemic

17. Bock-Moloney, M. C., et al. Cardiomyocyte survival after ischemia. Circulation, 114(5), 574–584 (2006).

18. Smart, N., et al. Epicardial activation/coronary neovascularization. Nature, 445(7120), 177–182 (2007).

19. Hinkel, R., et al. Cardiac function/infarct size. JACC, 56(11), 908–917 (2010).

20. Goldstein, A. L., & Badamchi-Zadeh, A. Cardioprotection via actin/mitochondrial stability. Int J Cardiol, 203, 623–631 (2016).

Neurologic & CNS

21. Xiong, Y., et al. Neurological function after TBI. J Neurosurg, 114(1), 102–115 (2011).

22. Morris, D. C., et al. Neurogenesis/remyelination. J Neurosci Res, 88(8), 1725–1737 (2010).

23. Zheng, W., et al. Neuronal survival in ischemic stroke. Neurosci Lett, 566, 63–68 (2014).

Anti-Inflammatory & Anti-Fibrotic

24. Sosne, G., et al. Anti-inflammatory pathways. J Immunol, 179(3), 1895–1903 (2007).

25. Yang, H., et al. TGF-β fibrosis inhibition. Cell Physiol Biochem, 31(1), 67–78 (2013).

26. Badamchi-Zadeh, A., et al. Immune modulation via thymosin peptides. Expert Opin Biol Ther, 15(8), 1205–1217 (2015).

Ophthalmic & Corneal

27. Sosne, G., et al. Corneal wound healing. Invest Ophthalmol Vis Sci, 48(1), 10–16 (2007).

28. Dunn, S., et al. Epithelial repair in dry eye. Cornea, 32(4), 407–413 (2013).

29. Sharif, Z. Ocular regenerative effects. Surv Ophthalmol, 56(5), 463–479 (2011).

Safety & Toxicology

30. Goldstein, A. L., et al. Safety of thymosin peptides in humans. Ann NY Acad Sci, 1112, 1–14 (2007).

31. Bock-Moloney, M. C., et al. Systemic safety preclinical. Toxicol Pathol, 39(7), 1101–1112 (2011).

32. FDA CFSAN & CDER. Thymosin peptides regulatory/safety. FDA, 2010–2023.